MARKET WIRE NEWS

Harnessing Nature's Wisdom: Gene-Editing Therapy For Cardiovascular Disease

Source: SeekingAlpha

2025-09-12 01:10:00 ET

By Shea Wihlborg

Introduction

Cardiovascular disease is the world’s leading killer and one of the most economically damaging, as its prevalence and costs have been rising. 1 While statins can reduce the risk of heart attacks by ~29%, 2 residual risk and poor long-term adherence—roughly half of patients discontinuing after a year—have left millions of people vulnerable. 3 The most common reasons for discontinuing statin treatment include experiencing or fear of developing side effects like muscle pain, perceived lack of benefit, and treatment fatigue from chronic dosing. 4 Not unique to statins, this pattern of poor adherence is widely observed in treatments for other chronic diseases and reflects the broader challenge of sustaining long-term medication use when benefits are not immediately felt and barriers to adherence persist. 5 ...

Read the full article on Seeking Alpha

For further details see:

Harnessing Nature's Wisdom: Gene-Editing Therapy For Cardiovascular Disease
Invesco S&P 500 Equal Weight Health Care ETF

NASDAQ: RSPH

RSPH Trading

-0.67% G/L:

$30.6131 Last:

43,102 Volume:

$30.87 Open:

mwn-ir Ad 300

RSPH Latest News

June 27, 2025 06:48:00 am
How to Take Advantage of moves in (RSPH)
May 14, 2025 12:16:00 pm
(RSPH) Investment Analysis and Advice

RSPH Stock Data

$761,959,100
23,510,000
N/A
N/A
US

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App